Monimus Capital Management LP Purchases Shares of 137,058 Roivant Sciences Ltd. (NASDAQ:ROIV)

Monimus Capital Management LP purchased a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 137,058 shares of the company’s stock, valued at approximately $1,621,000. Roivant Sciences accounts for 1.5% of Monimus Capital Management LP’s holdings, making the stock its 25th biggest position.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Nordea Investment Management AB lifted its stake in shares of Roivant Sciences by 22.5% in the 4th quarter. Nordea Investment Management AB now owns 282,834 shares of the company’s stock valued at $3,306,000 after purchasing an additional 52,031 shares in the last quarter. TOMS Capital Investment Management LP acquired a new position in shares of Roivant Sciences in the 3rd quarter valued at about $46,333,000. Barclays PLC lifted its stake in shares of Roivant Sciences by 19.7% in the 3rd quarter. Barclays PLC now owns 459,521 shares of the company’s stock valued at $5,302,000 after purchasing an additional 75,609 shares in the last quarter. Loomis Sayles & Co. L P lifted its stake in shares of Roivant Sciences by 13.3% in the 3rd quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company’s stock valued at $45,147,000 after purchasing an additional 458,601 shares in the last quarter. Finally, Retirement Systems of Alabama lifted its stake in shares of Roivant Sciences by 26.9% in the 3rd quarter. Retirement Systems of Alabama now owns 530,022 shares of the company’s stock valued at $6,116,000 after purchasing an additional 112,286 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Insider Activity

In other Roivant Sciences news, Director Sciences Ltd. Roivant purchased 16,845,010 shares of Roivant Sciences stock in a transaction on Monday, January 13th. The stock was bought at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the transaction, the director now owns 96,650,341 shares of the company’s stock, valued at $1,933,006,820. The trade was a 21.11 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Eric Venker sold 100,000 shares of the business’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $11.49, for a total value of $1,149,000.00. Following the transaction, the chief operating officer now owns 595,580 shares of the company’s stock, valued at $6,843,214.20. This trade represents a 14.38 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,388,170 shares of company stock worth $27,612,299. 7.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

ROIV has been the topic of several recent research reports. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $18.08.

Roivant Sciences Stock Up 2.3 %

ROIV stock opened at $10.66 on Friday. Roivant Sciences Ltd. has a 52-week low of $9.76 and a 52-week high of $13.06. The company has a market capitalization of $7.61 billion, a PE ratio of -71.06 and a beta of 1.26. The stock’s 50 day moving average is $10.81 and its two-hundred day moving average is $11.51.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, sell-side analysts anticipate that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.